FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.
DiagnaMed Holdings (CSE: DMED) has launched its third generative AI product to the marketplace. The firms latest product is focused on enabling patients to take control of their health.
Labelled as Dr. GenAI, the product is a medical chatbot powered by OpenAI’s ChatGPT. The tool has been designed to provide fast and personalized medical information, based on a persons medical condition. The tool, which the company says is not a replacement for doctors, is designed to assist patients that are seeking a better understanding of their symptoms, or looking for new health solution ideas.
Sponsored · Silver47 Exploration Inc.
“We are excited to launch our third generative AI health solution, Dr. GenAI, for people seeking health information based on their unique medical conditions. Dr. GenAI aligns with our objective of developing and commercializing OpenAI ChatGPT powered solutions for the healthcare market and incorporating them into our CERVAI™ generative AI brain health platform,” commented DiagnaMed CEO Fabio Chianelli.
The product is available free to consumers for up to 20 messages a month, after which users can subscribe for a monthly fee of $19.99. The subscription includes unlimited messages, and early access to new features.
The launch of Dr. GenAI follows the firms launch of PalGPT.ai, which provides consumers an AI companion for private conversations, and FormGPT.io, a generative AI data collection and analysis solution intended for the healthcare market.
READ: DiagnaMed Launches Division For Generative AI Healthcare Applications
The products have been launched under DiagnaMed’s Health GenAI division, which was established to focus on the development and commercialization of a suite of generative AI customizable applications that are powered by GPT-4. Generate AI within the healthcare market is said to become a $17 billion market by 2032, as per a report released by Market.us.
Dr. GenAI is said to encourage a person to be more active in their overall health, but may be prone to errors, and is not a replacement for doctors.
DiagnaMed Holdings last traded at $0.09 on the CSE.
FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of DiagnaMed Holdings. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
